Bausch Health Extends Tender Offer for DURECT Shares to Sept. 10

MT Newswires Live08-26

Bausch Health Companies (BHC) said Tuesday its subsidiary has extended the expiration date of its tender offer to acquire all of the outstanding shares of DURECT Corporation (DRPX) till Sept. 10 from the earlier deadline of Sept. 9.

Bausch Health, during July, had announced to acquire DURECT for $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million.

The company had said that this transaction bakes in with the potential for two additional net sales milestone payments of up to $350 million in the aggregate if the milestones are achieved before the earlier of the 10-year anniversary of the first commercial sale of larsucosterol in the US and December 31, 2045.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment